Neuronetics (STIM) Misses Q1 EPS by 4c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results
May 9, 2023 7:30 AM EDTMALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the company or Neuronetics) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2023.
First Quarter 2023 Highlights
First quarter 2023 revenue of $15.5 million, an increase of 10% over the first quarter of 2022U.S. treatment session revenue increased 12% over the first quarter of 2022Shipped... More